Contact
Please use this form to send email to PR contact of this press release:
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
TO:
Please use this form to send email to PR contact of this press release:
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
TO: